-- Creative Biolabs, the global leader in immunological assay development and microfluidic technology, is delighted to announce the expansion of its complement system testing portfolio by launching enhanced C1q binding test and C3b deposition assay services, as well as cutting-edge microfluidic platforms. The strategic integration offers unparalleled sensitivity, throughput, and custom-made solutions for researchers involved in immunotherapy, vaccine development, and autoimmune disease research.
Creative Biolabs' complement C1q binding assay enables scientists to determine the complement activation potential of biologics, including monoclonal antibodies, Fc-fusion proteins, and antigen-antibody complexes. Being the classical complement pathway initiator, C1q is the key player in immune surveillance. Its binding activity needs to be characterized in order to predict complement-dependent cytotoxicity (CDC) and therapeutic safety profiles.
They provide both ELISA-format and surface plasmon resonance (SPR) formats, which allow customers to choose between high-throughput screening or real-time kinetic profiling. With the provision of flexible ligand orientation, species customization, and the capacity for pairing with downstream complement assays (e.g., C3b, C4b, C5b-9), the service is tailored to suit a range of research needs.
To augment the C1q assay, the C3b deposition assay quantitates the deposition of C3b on cell surfaces—a central event in amplifying the complement cascade. The assay is important in determining drug efficacy, dissecting disease mechanisms, and profiling immune evasion strategies.
The simplified workflow of Creative Biolabs includes sample preparation, controlled complement activation, high-sensitivity detection by ELISA or flow cytometry, and professional data analysis. The clients receive comprehensive reports with quantitative data and statistical analysis, ensuring reproducibility and clarity.
What makes Creative Biolabs an equally powerful partner in this field is its profound experience and proprietary technology in the field of microfluidics. Scientists can leverage Creative Biolabs' advanced lab-on-a-chip platforms for integrating sample handling, reaction control, and detection—all within miniature, customizable devices. Such microfluidic systems minimize reagent use and enable high-throughput analysis of numerous samples, significantly accelerating research without sacrificing analytical precision.
By integrating immunological expertise with microfluidic engineering, Creative Biolabs allows scientists to develop deeper insights into complement biology more quickly and accurately. Whether you're developing next-generation biologics or investigating immune dysregulation, this integrated platform offers a scalable, customized solution that responds to the demands of modern biomedical research.
For more information, please visit https://www.creative-biolabs.com/complement-therapeutics/.
About Creative Biolabs
Creative Biolabs is a global leading custom service biotechnology company, specialized in antibody engineering, immunoassay development, and microfluidics technology. From complement therapeutics to organ-on-a-chip, the company is committed to advancing science through precision, flexibility, and collaboration.
Contact Info:
Name: Candy Swift
Email: Send Email
Organization: Creative Biolabs
Address: Shirley, NY 11967, USA
Phone: 6318306441
Website: https://www.creative-biolabs.com/complement-therapeutics/
Release ID: 89167878
Google
RSS